Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Payables (2016 - 2025)

Historic Payables for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $474000.0.

  • Avalo Therapeutics' Payables fell 7382.66% to $474000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $474000.0, marking a year-over-year decrease of 7382.66%. This contributed to the annual value of $283000.0 for FY2024, which is 3654.71% down from last year.
  • Per Avalo Therapeutics' latest filing, its Payables stood at $474000.0 for Q3 2025, which was down 7382.66% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Payables ranged from a high of $36.9 million in Q1 2022 and a low of $283000.0 during Q4 2024
  • Moreover, its 5-year median value for Payables was $2.4 million (2025), whereas its average is $8.6 million.
  • Its Payables has fluctuated over the past 5 years, first surged by 177084.62% in 2021, then plummeted by 9560.07% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Payables stood at $3.4 million in 2021, then soared by 161.56% to $8.8 million in 2022, then tumbled by 94.94% to $446000.0 in 2023, then plummeted by 36.55% to $283000.0 in 2024, then soared by 67.49% to $474000.0 in 2025.
  • Its Payables stands at $474000.0 for Q3 2025, versus $2.4 million for Q2 2025 and $681000.0 for Q1 2025.